Review



mouse monoclonal antibody against fn1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    Proteintech mouse monoclonal antibody against fn1
    Log2 fold change in <t>FN1</t> gene expression in GC tissues. (A) FN1 expression in tumor tissues compared with that in normal tissues. (B) FN1 expression in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. (C) FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. Error bars represent 95% confidence interval. *P<0.05 and **P<0.01 vs. normal tissue. FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; ns, non-significant.
    Mouse Monoclonal Antibody Against Fn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 99/100, based on 700 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal antibody against fn1/product/Proteintech
    Average 99 stars, based on 700 article reviews
    mouse monoclonal antibody against fn1 - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "High expression of fibronectin 1 indicates poor prognosis in gastric cancer"

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    Journal: Oncology Letters

    doi: 10.3892/ol.2019.11088

    Log2 fold change in FN1 gene expression in GC tissues. (A) FN1 expression in tumor tissues compared with that in normal tissues. (B) FN1 expression in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. (C) FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. Error bars represent 95% confidence interval. *P<0.05 and **P<0.01 vs. normal tissue. FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; ns, non-significant.
    Figure Legend Snippet: Log2 fold change in FN1 gene expression in GC tissues. (A) FN1 expression in tumor tissues compared with that in normal tissues. (B) FN1 expression in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. (C) FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. Error bars represent 95% confidence interval. *P<0.05 and **P<0.01 vs. normal tissue. FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; ns, non-significant.

    Techniques Used: Gene Expression, Expressing

    Forest plot and meta-analysis of FN1 expression in gastric cancer. (A) Forest plot of the log2 fold change in FN1 expression in tumor tissues compared with that in normal tissues. (B) Forest plot of the log2 fold change in FN1 expression in the advanced T stage group (T2 + T3 + T4) compared with that in the early T stage group (T1). (C) Forest plot of the log2 fold change in FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) Forest plot of the log2 fold change in FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. (E) Forest plot of the comparison of overall survival in patients with gastric cancer with high and low FN1 expression (The gene expression value was equal to three, the first two-thirds were defined as high expression and the last one-third as low expression). FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; CI, confidence interval.
    Figure Legend Snippet: Forest plot and meta-analysis of FN1 expression in gastric cancer. (A) Forest plot of the log2 fold change in FN1 expression in tumor tissues compared with that in normal tissues. (B) Forest plot of the log2 fold change in FN1 expression in the advanced T stage group (T2 + T3 + T4) compared with that in the early T stage group (T1). (C) Forest plot of the log2 fold change in FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) Forest plot of the log2 fold change in FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. (E) Forest plot of the comparison of overall survival in patients with gastric cancer with high and low FN1 expression (The gene expression value was equal to three, the first two-thirds were defined as high expression and the last one-third as low expression). FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; CI, confidence interval.

    Techniques Used: Expressing, Comparison, Gene Expression

    Kaplan-Meier survival curves of the high- and low- FN1 expression groups in six cohorts. Survival curves for the following datasets: (A) GSE14208; (B) GSE15459; (C) GSE29272; (D) GSE34942; (E) GSE66229 and (F) TCGA. FN1 , fibronectin 1; TCGA, The Cancer Genome Atlas.
    Figure Legend Snippet: Kaplan-Meier survival curves of the high- and low- FN1 expression groups in six cohorts. Survival curves for the following datasets: (A) GSE14208; (B) GSE15459; (C) GSE29272; (D) GSE34942; (E) GSE66229 and (F) TCGA. FN1 , fibronectin 1; TCGA, The Cancer Genome Atlas.

    Techniques Used: Expressing

    Immunohistochemical analysis of FN1 in GC. (A) Normal gastric mucosa exhibited negative staining for FN1 . (B-D) E- FN1 expression in GS tissues. (B) Expression score, 0; (C) expression score, 6; and (D) expression score, 12. (E-H) S- FN1 expression in in GS tissues. (E) No expression; (F) low expression; (G) medium expression; and (H) high expression. Magnification, ×200. GC, gastric cancer; FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 .
    Figure Legend Snippet: Immunohistochemical analysis of FN1 in GC. (A) Normal gastric mucosa exhibited negative staining for FN1 . (B-D) E- FN1 expression in GS tissues. (B) Expression score, 0; (C) expression score, 6; and (D) expression score, 12. (E-H) S- FN1 expression in in GS tissues. (E) No expression; (F) low expression; (G) medium expression; and (H) high expression. Magnification, ×200. GC, gastric cancer; FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 .

    Techniques Used: Immunohistochemical staining, Negative Staining, Expressing

    Patient characteristics based on the immunohistochemistry results of FN1 expression in gastric cancer.
    Figure Legend Snippet: Patient characteristics based on the immunohistochemistry results of FN1 expression in gastric cancer.

    Techniques Used: Immunohistochemistry, Expressing

    Association between epithelial and stromal expression of FN1 in gastric cancer.
    Figure Legend Snippet: Association between epithelial and stromal expression of FN1 in gastric cancer.

    Techniques Used: Expressing

    The prognostic significance of FN1 in patients with gastric cancer based on immunohistochemistry. (A) Kaplan-Meier analysis of OS based on E- FN1 expression in 190 patients. (B) Kaplan-Meier analysis of OS based on S- FN1 expression in 190 patients. (C and D) Kaplan-Meier analysis of OS based on S- FN1 expression in patients with (C) TNM stage I+II (D) and III+IV gastric cancer. FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 ; TNM, Tumor-Node-Metastasis; OS, overall survival.
    Figure Legend Snippet: The prognostic significance of FN1 in patients with gastric cancer based on immunohistochemistry. (A) Kaplan-Meier analysis of OS based on E- FN1 expression in 190 patients. (B) Kaplan-Meier analysis of OS based on S- FN1 expression in 190 patients. (C and D) Kaplan-Meier analysis of OS based on S- FN1 expression in patients with (C) TNM stage I+II (D) and III+IV gastric cancer. FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 ; TNM, Tumor-Node-Metastasis; OS, overall survival.

    Techniques Used: Immunohistochemistry, Expressing

    Multivariate analysis of overall survival in 190 patients with gastric cancer.
    Figure Legend Snippet: Multivariate analysis of overall survival in 190 patients with gastric cancer.

    Techniques Used: Expressing



    Similar Products

    mouse monoclonal primary antibodies against fn1  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology mouse monoclonal primary antibodies against fn1
    Immunostaining of cells for <t>CDH1</t> (A) and FN1 (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.
    Mouse Monoclonal Primary Antibodies Against Fn1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal primary antibodies against fn1/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse monoclonal primary antibodies against fn1 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mouse monoclonal antibody against fn1  (Proteintech)
    99
    Proteintech mouse monoclonal antibody against fn1
    Log2 fold change in <t>FN1</t> gene expression in GC tissues. (A) FN1 expression in tumor tissues compared with that in normal tissues. (B) FN1 expression in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. (C) FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. Error bars represent 95% confidence interval. *P<0.05 and **P<0.01 vs. normal tissue. FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; ns, non-significant.
    Mouse Monoclonal Antibody Against Fn1, supplied by Proteintech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal antibody against fn1/product/Proteintech
    Average 99 stars, based on 1 article reviews
    mouse monoclonal antibody against fn1 - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    mouse monoclonal primary antibodies against cdh1 (e-cadherin) and fn1 (fibronectin)  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology mouse monoclonal primary antibodies against cdh1 (e-cadherin) and fn1 (fibronectin)
    Immunostaining of cells for CDH1 (A) and <t>FN1</t> (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.
    Mouse Monoclonal Primary Antibodies Against Cdh1 (E Cadherin) And Fn1 (Fibronectin), supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal primary antibodies against cdh1 (e-cadherin) and fn1 (fibronectin)/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    mouse monoclonal primary antibodies against cdh1 (e-cadherin) and fn1 (fibronectin) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Immunostaining of cells for CDH1 (A) and FN1 (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.

    Journal: Journal of Ovarian Research

    Article Title: Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells

    doi: 10.1186/1757-2215-7-12

    Figure Lengend Snippet: Immunostaining of cells for CDH1 (A) and FN1 (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.

    Article Snippet: The slides were incubated with mouse monoclonal primary antibodies against CDH1 (E-cadherin) and FN1 (Fibronectin, 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 5% BSA for 1 hour at room temperature.

    Techniques: Immunostaining, Transfection, Staining

    Log2 fold change in FN1 gene expression in GC tissues. (A) FN1 expression in tumor tissues compared with that in normal tissues. (B) FN1 expression in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. (C) FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. Error bars represent 95% confidence interval. *P<0.05 and **P<0.01 vs. normal tissue. FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; ns, non-significant.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Log2 fold change in FN1 gene expression in GC tissues. (A) FN1 expression in tumor tissues compared with that in normal tissues. (B) FN1 expression in the advanced T stage (T2 + T3 + T4) group compared with that in the early T stage (T1) group. (C) FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. Error bars represent 95% confidence interval. *P<0.05 and **P<0.01 vs. normal tissue. FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; ns, non-significant.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Gene Expression, Expressing

    Forest plot and meta-analysis of FN1 expression in gastric cancer. (A) Forest plot of the log2 fold change in FN1 expression in tumor tissues compared with that in normal tissues. (B) Forest plot of the log2 fold change in FN1 expression in the advanced T stage group (T2 + T3 + T4) compared with that in the early T stage group (T1). (C) Forest plot of the log2 fold change in FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) Forest plot of the log2 fold change in FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. (E) Forest plot of the comparison of overall survival in patients with gastric cancer with high and low FN1 expression (The gene expression value was equal to three, the first two-thirds were defined as high expression and the last one-third as low expression). FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; CI, confidence interval.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Forest plot and meta-analysis of FN1 expression in gastric cancer. (A) Forest plot of the log2 fold change in FN1 expression in tumor tissues compared with that in normal tissues. (B) Forest plot of the log2 fold change in FN1 expression in the advanced T stage group (T2 + T3 + T4) compared with that in the early T stage group (T1). (C) Forest plot of the log2 fold change in FN1 expression in the low differentiation group (high tumor grade) compared with that in the high differentiation group (intermediate and low tumor grade). (D) Forest plot of the log2 fold change in FN1 expression in the high clinical TNM stage (III+IV) group compared with that in the low clinical TNM stage (I+II) group. (E) Forest plot of the comparison of overall survival in patients with gastric cancer with high and low FN1 expression (The gene expression value was equal to three, the first two-thirds were defined as high expression and the last one-third as low expression). FN1 , fibronectin 1; TNM, Tumor-Node-Metastasis; CI, confidence interval.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Expressing, Comparison, Gene Expression

    Kaplan-Meier survival curves of the high- and low- FN1 expression groups in six cohorts. Survival curves for the following datasets: (A) GSE14208; (B) GSE15459; (C) GSE29272; (D) GSE34942; (E) GSE66229 and (F) TCGA. FN1 , fibronectin 1; TCGA, The Cancer Genome Atlas.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Kaplan-Meier survival curves of the high- and low- FN1 expression groups in six cohorts. Survival curves for the following datasets: (A) GSE14208; (B) GSE15459; (C) GSE29272; (D) GSE34942; (E) GSE66229 and (F) TCGA. FN1 , fibronectin 1; TCGA, The Cancer Genome Atlas.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Expressing

    Immunohistochemical analysis of FN1 in GC. (A) Normal gastric mucosa exhibited negative staining for FN1 . (B-D) E- FN1 expression in GS tissues. (B) Expression score, 0; (C) expression score, 6; and (D) expression score, 12. (E-H) S- FN1 expression in in GS tissues. (E) No expression; (F) low expression; (G) medium expression; and (H) high expression. Magnification, ×200. GC, gastric cancer; FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 .

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Immunohistochemical analysis of FN1 in GC. (A) Normal gastric mucosa exhibited negative staining for FN1 . (B-D) E- FN1 expression in GS tissues. (B) Expression score, 0; (C) expression score, 6; and (D) expression score, 12. (E-H) S- FN1 expression in in GS tissues. (E) No expression; (F) low expression; (G) medium expression; and (H) high expression. Magnification, ×200. GC, gastric cancer; FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 .

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Immunohistochemical staining, Negative Staining, Expressing

    Patient characteristics based on the immunohistochemistry results of FN1 expression in gastric cancer.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Patient characteristics based on the immunohistochemistry results of FN1 expression in gastric cancer.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Immunohistochemistry, Expressing

    Association between epithelial and stromal expression of FN1 in gastric cancer.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Association between epithelial and stromal expression of FN1 in gastric cancer.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Expressing

    The prognostic significance of FN1 in patients with gastric cancer based on immunohistochemistry. (A) Kaplan-Meier analysis of OS based on E- FN1 expression in 190 patients. (B) Kaplan-Meier analysis of OS based on S- FN1 expression in 190 patients. (C and D) Kaplan-Meier analysis of OS based on S- FN1 expression in patients with (C) TNM stage I+II (D) and III+IV gastric cancer. FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 ; TNM, Tumor-Node-Metastasis; OS, overall survival.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: The prognostic significance of FN1 in patients with gastric cancer based on immunohistochemistry. (A) Kaplan-Meier analysis of OS based on E- FN1 expression in 190 patients. (B) Kaplan-Meier analysis of OS based on S- FN1 expression in 190 patients. (C and D) Kaplan-Meier analysis of OS based on S- FN1 expression in patients with (C) TNM stage I+II (D) and III+IV gastric cancer. FN1 , fibronectin 1; S- FN1 , stromal FN1 ; E- FN1 , epithelial FN1 ; TNM, Tumor-Node-Metastasis; OS, overall survival.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Immunohistochemistry, Expressing

    Multivariate analysis of overall survival in 190 patients with gastric cancer.

    Journal: Oncology Letters

    Article Title: High expression of fibronectin 1 indicates poor prognosis in gastric cancer

    doi: 10.3892/ol.2019.11088

    Figure Lengend Snippet: Multivariate analysis of overall survival in 190 patients with gastric cancer.

    Article Snippet: A mouse monoclonal antibody against FN1 (cat. no. 66042-1-Ig; ProteinTech Group, Inc.) was used at a 1:600 dilution at pH 9.0.

    Techniques: Expressing

    Immunostaining of cells for CDH1 (A) and FN1 (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.

    Journal: Journal of Ovarian Research

    Article Title: Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells

    doi: 10.1186/1757-2215-7-12

    Figure Lengend Snippet: Immunostaining of cells for CDH1 (A) and FN1 (B) proteins. (i) HEY cells (not transfected), HEY cells transfected with (ii) nc-miR, (iii) miR-200a, (iv) miR-141, (v) miR-200b, (vi) miR-200c, and (vii) miR-429. DAPI was used to stain the cell nuclei. Scale bars, 50 μm.

    Article Snippet: The slides were incubated with mouse monoclonal primary antibodies against CDH1 (E-cadherin) and FN1 (Fibronectin, 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 5% BSA for 1 hour at room temperature.

    Techniques: Immunostaining, Transfection, Staining

    Prediction of miR-200 binding sites on FN1, ZEB1, ZEB2, KRT7, KRT8 and KRT18 mRNAs

    Journal: Journal of Ovarian Research

    Article Title: Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells

    doi: 10.1186/1757-2215-7-12

    Figure Lengend Snippet: Prediction of miR-200 binding sites on FN1, ZEB1, ZEB2, KRT7, KRT8 and KRT18 mRNAs

    Article Snippet: The slides were incubated with mouse monoclonal primary antibodies against CDH1 (E-cadherin) and FN1 (Fibronectin, 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in 5% BSA for 1 hour at room temperature.

    Techniques: Binding Assay